Product Name: EphB2 (605-620)
Product Number: PE-01BCU95
Size: 200 µg      Price:51.00
1 mg      $US102.00
5 mg      224.00
Peptide Name: EphB2 (605-620)

Product Use: Services as a blocking peptide for use with the EphB2-BKCD rabbit polyclonal antibody (Cat. No.: AB-NK267-1) that is also available from Kinexus. The peptide sequence is located just before the kinase catalytic domain; Note the seqence is identical in EPHB1, EPHB2, EPHB3 an EPHB4.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: PNEAVREFAKEIDISC

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1820 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: EphB2 pan-specific antibody (Cat. No.: AB-NK267-1)

Scientific Background: EphB2 is a protein-tyrosine kinase of the TK group and Eph family. It is a receptor kinase, and is activated by binding ephrin-B1, B2, or B3. Eph and Eph receptors are associated with nervous system development events, and lead to contact-dependent signalling through adjacent cells. Eph receptors are widely expressed in early development and rarely detected in adult tissues. EphB2 signalling has an important role in the development and structural organization of neurons. EphB2 is also involved in angiogenesis, palate development and inner ear development through endolymph production. EphB2 appears to be a tumour suppressor protein (TSP). The active form of the protein kinase normally acts to inhibit tumour cell proliferation. EphB2 mutations have been found in prostate cancer. Most prostate cancers are adenocarcinomas that derived from acini of the prostatic ducts. K1019X mutation was significantly more common in African American probands. Over-expression of EphB2 has been frequently detected in both well-differentiated adenocarcinomas (10 of 13) and poorly differentiated adenocarcinomas (9 of 14). EphB2 expression restricts the invasiveness of colorectal cancer cells into ephrin-B1 expressing cell populations, thus segregating cancer cells from normal cells.